Research programme: anthrax vaccine - Celldex Therapeutics IncAlternative Names: CDX-2301
Latest Information Update: 14 Apr 2011
At a glance
- Originator Celldex Therapeutics Inc
- Class Anthrax vaccines
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 22 Feb 2007 Preclinical trials in Anthrax in USA (Intranasal)
- 22 Feb 2007 Preclinical trials in Anthrax in USA (IM)